Treatment of Reticular Erythematous Mucinosis With UV-A1 Radiation | Dermatology | JAMA Dermatology | JAMA Network
[Skip to Navigation]
Sign In
The Cutting Edge
June 2004

Treatment of Reticular Erythematous Mucinosis With UV-A1 Radiation

Author Affiliations

University of Cologne, Cologne, Germany



Arch Dermatol. 2004;140(6):660-662. doi:10.1001/archderm.140.6.660

Reticular erythematous mucinosis (REM) is a rare chronic dermatosis that is typically characterized by reticular macular erythema or erythematous papules and plaques on the central area of the chest and back of middle-aged women. The pathogenesis and etiology of REM remain undefined at present. Several factors have been associated with the induction of the syndrome, including viral processes, immunological disturbances, and solar irradiation.1-8

Report of case

A 44-year-old woman presented to our outpatient clinic with a 4-year history of symmetrical netlike macular erythema and erythematous papules on the central area of her chest (Figure 1). She stated that exposure to light did not seem to aggravate her condition. Her medical history was unremarkable except for a goiter, and laboratory tests revealed normal of plasma levels of thyroxine and thyrotropin. Her family history was not contributory. Thyroid hormone, antinuclear antibody, IgA, IgG, IgM, and serum complement levels were normal. Antibodies to native (single- and double-stranded) DNA were absent. Hematoxylin-eosin staining of biopsy specimens of lesional skin revealed a perivascular and perifollicular lymphomononuclear cell infiltrate. Alcian blue staining revealed mucin deposits in the upper dermis and a basement membrane of normal thickness. Direct immunofluorescence examination was negative for immunoglobulin depositions and slightly positive for complement (C3) depositions. On the basis of the clinical picture and the histologic findings, REM was diagnosed.

Figure 1. 
The patient presented with a symmetrical reticular macular erythema and erythematous papules on the central area of her chest.

The patient presented with a symmetrical reticular macular erythema and erythematous papules on the central area of her chest.

Therapeutic challenge

Successful therapy of REM with chloroquine has been reported.1-12 Other treatment alternatives (UV-B, laser, glucocorticoids, cyclosporine) have had variable efficacy.1-12 Since treatment with chloroquine was refused by the patient, another therapeutic option was needed. Therefore, UV-A1 (340-400 nm) therapy was considered.


To exclude photosensitivity, photoprovocation testing was performed with UV-A and UV-B on the patient's normal back skin using a commercially available phototesting device (SBB LT 400 Multitester; Saalmann GmbH, Herford, Germany). The minimal erythema dose was determined by applying graded doses of UV-A (1-8 J/cm−2) and UV-B (10-80 mJ/cm−2). It was defined as the lowest irradiation dose necessary to produce minimal perceptive erythema of the test site at 20 minutes (UV-A) and 24 hours (UV-B) after irradiation. Also, UV-A (60 J/cm−2) and UV-B (90 mJ/cm−2) irradiation was applied for a photoprovocation test on the next 3 days, and the irradiated sites were checked for skin changes at days 4 and 5 and weeks 1, 3, and 6 after the first application. After no abnormal response was observed, UV-A1 irradiation of the lesional skin of the chest was started at a dose of 40 J/cm−2. Irradiations were performed 5 days a week, and the doses were increased by 10 J/cm−2daily to a maximum dose of 90 J/cm−2. After 18 UV-A1 irradiations and a cumulative dose of 1210 J/cm−2, the patient's lesions completely cleared (Figure 2). Her skin remained clear for 10 months. A minor recurrence was treated with UV-A1 at doses of up to 90 J/cm−2. After 16 additional irradiations (cumulative dose, 1420 J/cm−2), the lesions again completely cleared. No further recurrence was observed until December 2002.

Figure 2. 
The patient's skin lesions after 18 UV-A1 irradiations and a cumulative dose of 1210 J/cm−2.

The patient's skin lesions after 18 UV-A1 irradiations and a cumulative dose of 1210 J/cm−2.


Initially reported as a "plaque-like [form of] cutaneous mucinosis (PCM)"13 and REM syndrome,1 these conditions were recognized as part of the spectrum of the same disorder.2,14,15 The cutaneous lesions range from erythematous, indurated papules and plaques to netlike macular erythema. The central chest and/or upper back area is a preferentially involved location.10,11 The arms, face, and abdomen are less frequently affected. Predominant histopathologic findings include expanded vessels, perivascular and perifollicular round cell infiltration, and (alcian blue–positive) mucin depositions between the collagen fibers of the upper dermis. Antimalarial therapy has reportedly been the most effective treatment, resulting in prompt clinical improvement within a month or less in the majority of patients.1,10,11 Other treatment regimens include topical and systemic corticosteroids, sometimes in combination with UV-B irradiation and cyclosporine.1-12

In approximately 20% of cases, REM may be associated with a variety of systemic disorders, especially autoimmune diseases such as discoid lupus erythematosus, idiopathic thrombocytopenic purpura, and diabetes mellitus, but also with malignancies and thyroid diseases.2,4 Other factors that have been observed to promote exacerbation of REM include menstruation, pregnancy, heat, x-ray therapy, and excitement. Sun exposure has also been reported to induce new skin lesions and to worsen the condition in several patients.1-6,10,13,16 Interestingly, an abnormal response was not observed in most patients when they were phototested with UV-A and UV-B irradiation.1,14,17 Morrison et al6 described a patient who developed biopsy-confirmed REM skin lesions in response to irradiation with UV-B, UV-C, and solar stimulation 28 days after exposure. On the other hand, no rash was induced when UV-A, visible, infrared, or psoralen–UV-A irradiation was applied. Furthermore, several patients were described in whom exposure to sunlight appeared to be associated with improvement of the syndrome and clearance of the skin lesions.2,13,18

In REM skin lesions, mucin deposits consist mainly of hyaluronic acid, as has clearly been shown by analysis of the glycosaminoglycan content.1-3,19

Ultraviolet A1, directly or indirectly, via induction of proinflammatory cytokines such as interleukin 1-β, can induce matrix-degrading enzymes such as proteoglycanase in dermal fibroblasts, which may lead to an increased degradation of hyaluronic acid depositions.20 In a similar way, these cytokines can result in a down-regulation of hyaluronic acid synthesis in REM fibroblasts.21,22 Moreover, reactive oxygen species such as singlet oxygen, superoxide anion, and the hydroxyl radical—as they are all produced on UV (especially UV-A) irradiation—have been shown to lead to fragmentation and damage of hyaluronic acid.23

Because of their different wavelengths, UV-A, and particularly UV-A1, is able to permeate deeper into the dermis than UV-B. This physical quality might explain why UV-B irradiation, even in large doses, was an ineffective monotherapy in this case,24 while UVA-1 treatment led to a complete resolution of skin changes.

In summary, UV-A1 therapy represents an effective alternative in the treatment of REM.


Corresponding author: Nicolas Hunzelmann, MD, Department of Dermatology, University of Cologne, Joseph-Stelzmann Strasse 9, 50924 Cologne, Germany (e-mail:

Accepted for publication July 16, 2003.

The authors have no relevant financial interest in this article.


Clinicians, local and regional societies, residents, and fellows are invited to submit cases of challenges in management and therapeutics to this section. Cases should follow the established pattern. Submit 4 double-spaced copies of the manuscript with right margins nonjustified and 4 sets of the illustrations. Photomicrographs and illustrations must be clear and submitted as positive color transparencies (35-mm slides) or black-and-white prints. Do not submit color prints unless accompanied by original transparencies. Material should be accompanied by the required copyright transfer statement, as noted in "Instructions for Authors." Material for this section should be submitted to George J. Hruza, MD, Laser and Dermatologic Surgery Center Inc, 14377 Woodlake Dr, Suite 111, St Louis, MO 63017.

Steigleder  GKGartmann  HLinker  U REM syndrome: reticular erythematous mucinosis (round-cell erythematosis): a new entity?  Br J Dermatol. 1974;91191- 199PubMedGoogle ScholarCrossref
Quimby  SRPerry  HO Plaquelike cutaneous mucinosis: its relationship to reticular erythematous mucinosis  J Am Acad Dermatol. 1982;6856- 861PubMedGoogle ScholarCrossref
Bleehen  SSSlater  DNMahood  JChurch  RE Reticular erythematous mucinosis: light and electron microscopy, immunofluorescence and histochemical findings  Br J Dermatol. 1982;1069- 18PubMedGoogle ScholarCrossref
Braddock  SWDavis  CSDavis  RB Reticular erythematous mucinosis and thrombocytopenic purpura: report of a case and review of world literature, including plaquelike cutaneous mucinosis  J Am Acad Dermatol. 1988;19859- 868PubMedGoogle ScholarCrossref
Zaki  IShall  LMillard  LG Reticular erythematous mucinosis syndrome and a monoclonal IgG kappa paraprotein: is there an association?  Br J Dermatol. 1993;129347- 348PubMedGoogle ScholarCrossref
Morrison  WLShea  CRParrish  JA Reticular erythematous mucinosis syndrome: report of two cases  Arch Dermatol. 1979;1151340- 1342PubMedGoogle ScholarCrossref
Bulengo-Ransby  SMEllis  CNGriffiths  CE  et al.  Failure of reticular erythematous mucinosis to respond to cyclosporine  J Am Acad Dermatol. 1992;27825- 828PubMedGoogle ScholarCrossref
McFadden  NLarsen  TE Reticular erythematous mucinosis and photosensitivity: a case study  Photodermatology. 1988;5270- 272PubMedGoogle Scholar
Cohen  PRRabinowitz  ADRuszkowski  AMDeLeo  V Reticular erythematous mucinosis syndrome: review of the world literature and report of the syndrome in a prepubertal child  Pediatr Dermatol. 1990;71- 10PubMedGoogle ScholarCrossref
Dodd  HJSarkany  ISadrubin  A Reticular erythematous mucinosis syndrome  Clin Exp Dermatol. 1987;1236- 39PubMedGoogle ScholarCrossref
Funai  TAoki  T Reticular erythematous mucinosis syndrome: a case report  J Dermatol. 1986;13213- 216PubMedGoogle Scholar
Yamazaki  SKatyama  IKurumaji  Y  et al.  Treatment of reticular erythematous mucinosis with a large dose of ultraviolet B radiation and steroid impregnated tape  J Dermatol. 1999;26115- 118PubMedGoogle Scholar
Perry  HOKierland  RRMontgomery  H Plaque-like form of cutaneous mucinosis  Arch Dermatol. 1960;82980- 985PubMedGoogle ScholarCrossref
Keczekes  KJadhav  P REM syndrome (reticular erythematous mucinosis): report of a further case or variant of it  Arch Dermatol. 1977;113335- 338PubMedGoogle ScholarCrossref
Bleehen  SSSlater  DN Reticular erythematous mucinosis versus plaquelike cutanteous mucinosis  J Am Acad Dermatol. 1983;8125PubMedGoogle ScholarCrossref
Dijkmans  BACBergman  WEulderink  FMeijers  KAE Reticular erythematous mucinosis syndrome in a patient with polyarthritis  Acta Derm Venereol. 1986;66442- 445PubMedGoogle Scholar
Dal  B-LLarsen  TE Reticular erythematous mucinosis syndrome: report of a case  Acta Derm Venereol. 1977;57465- 467PubMedGoogle Scholar
Allen  BR REM syndrome  Br J Dermatol. 1978;9938PubMedGoogle ScholarCrossref
Izumi  TTajima  SHarada  RNishikawa  T Reticular erythematous mucinosis syndrome: glycosaminoglycan synthesis by fibroblasts and abnormal response to interleukin-1 beta  Dermatology. 1996;19241- 45PubMedGoogle ScholarCrossref
Duncan  MRBerman  B Differential regulation of collagen, glycosaminoglycan, fibronectin, and collagenase activity production in cultured human adult dermal fibroblasts by interleukin-1 alpha and beta  J Invest Dermatol. 1989;92699- 706PubMedGoogle ScholarCrossref
Babu  MDiegelmann  ROliver  N Keloid fibroblasts exhibit an altered response to TGFβ  J Invest Dermatol. 1992;99650- 655PubMedGoogle ScholarCrossref
Russell  SBTrupin  JSMyles  JC  et al.  Differential glucocorticoid regulation of collagen mRNAs in human dermal fibroblasts  J Biol Chem. 1989;26413730- 13735PubMedGoogle Scholar
Frati  EKhatib  AMFront  P  et al.  Degradation of hyaluronic acid by photosensitized riboflavin in vitro: modulation of the effect by transition metals, radical quenchers, and metal chelators  Free Radic Biol Med. 1997;221139- 1144PubMedGoogle ScholarCrossref
Yamazaki  SKatayama  IKurumaji  Y  et al.  Treatment of reticular erythematous mucinosis with a large dose of ultraviolet B radiation and steroid impregnated tape  J Dermatol. 1999;26115- 118PubMedGoogle Scholar